Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma

被引:4
作者
Lv, Tian-Run [1 ]
Hu, Hai-Jie [1 ]
Ma, Wen-Jie [1 ]
Liu, Fei [1 ]
Jin, Yan-Wen [1 ]
Li, Fu-Yu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Biliary Tract Surg, Gen Surg, Chengdu 610041, Sichuan, Peoples R China
来源
EJSO | 2024年 / 50卷 / 01期
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Combined hepatocellular carcinoma and; cholangiocarcinoma; Prognostic factors; Surgery; Prognosis; LONG-TERM PROGNOSIS; ACID-ENHANCED MRI; CLINICOPATHOLOGICAL FEATURES; LIVER-TRANSPLANTATION; INTRAHEPATIC CHOLANGIOCARCINOMA; MICROVASCULAR INVASION; PATHOLOGICAL FEATURES; CURATIVE RESECTION; SURGICAL-TREATMENT; CLINICAL-FEATURES;
D O I
10.1016/j.ejso.2023.107279
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Combined hepatocellular carcinoma and cholangiocarcinoma (CHCC-CC) is a rare subtype of primary liver malignancy and has been treated equally as intra-hepatic cholangiocarcinoma (IHCC) according to the 8th AJCC staging system. Owing to its rarity, its prognostic factors have been rarely explored and defined.Methods: PubMed, EMBASE, the Cochrane Library and Web of Science were searched up till January 1st, 2023 and eligible studies were restricted to studies reported prognostic factors of resected CHCC-CC. Standard Parmar modifications were used to determine pooled univariable hazard ratios (HRs).Results: A total of eleven studies with 1286 patients with resected classical CHCC-CC were finally included. Pooled results indicated that serum tumor biomarkers, including AFP, CA199, and CEA, were prognostic factors for postoperative overall survival (OS) and disease-free survival (DFS). Moreover, liver cirrhosis (P = 0.010), HBV infection (P = 0.030), and HCV infection (P < 0.001) were prognostic factors for OS. Age (HR = 1.03, P = 0.005) was a prognostic factor for DFS. Tumor size (OS: HR = 2, P < 0.001, DFS: HR = 2.15, P < 0.001), tumor number (OS: HR = 2.05, P < 0.001; DFS: HR = 1.96, P = 0.006), surgical margin (OS: HR = 2.33, <0.001001; DFS: HR = 2.35, P < 0.001), node metastasis (OS: HR = 2.96, P < 0.001; DFS: HR = 2.1, P < 0.001), vascular invasion (OS: HR = 2.17, P < 0.001; DFS: HR = 2.64, P < 0.001), and postoperative prophylactic trans-arterial chemotherapy embolization (PPTACE) (OS: HR = 1.67, P = 0.04; DFS: HR = 2.31, P < 0.001) were common prognostic factors for OS and DFS.Conclusion: Various risk factors unmentioned in the 8th AJCC staging system were identified. These promising findings would facilitate a more personalized predictive model and help clinicians to stratify patients with different survival outcomes.
引用
收藏
页数:15
相关论文
共 86 条
[81]   Combined hepatocellular-cholangiocarcinoma An analysis of clinicopathological characteristics after surgery [J].
Zhang, Hao ;
Yu, Xiaojiong ;
Xu, Jian ;
Li, Juan ;
Zhou, Yao .
MEDICINE, 2019, 98 (38)
[82]   Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis [J].
Zhang, Xu-Feng ;
Xue, Feng ;
Dong, Ding-Hui ;
Weiss, Matthew ;
Popescu, Irinel ;
Marques, Hugo P. ;
Aldrighetti, Luca ;
Maithel, Shishir K. ;
Pulitano, Carlo ;
Bauer, Todd W. ;
Shen, Feng ;
Poultsides, George A. ;
Soubrane, Oliver ;
Martel, Guillaume ;
Koerkamp, Bas Groot ;
Itaru, Endo ;
Lv, Yi ;
Pawlik, Timothy M. .
ANNALS OF SURGERY, 2021, 274 (06) :E1187-E1195
[83]   Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis [J].
Zhou, Changwu ;
Wang, Yi ;
Ma, Li ;
Qian, Xianling ;
Yang, Chun ;
Zeng, Mengsu .
EUROPEAN RADIOLOGY, 2022, 32 (01) :78-88
[84]   Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study [J].
Zhou, Yu-Wen ;
Li, Qing-Fang ;
Chen, Yue-Yun ;
Wang, Kai ;
Pu, Dan ;
Chen, Xiao-Rong ;
Li, Chun-Hong ;
Jiang, Li ;
Wang, Yan ;
Li, Qiu ;
Yang, Yu ;
Gou, Hong-Feng ;
Bi, Feng ;
Liu, Ji-Yan ;
Chen, Ye ;
Qiu, Meng .
EJSO, 2022, 48 (07) :1559-1566
[85]   SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma [J].
Zhu, Andrew X. ;
Rosmorduc, Olivier ;
Evans, T. R. Jeffry ;
Ross, Paul J. ;
Santoro, Armando ;
Carrilho, Flair Jose ;
Bruix, Jordi ;
Qin, Shukui ;
Thuluvath, Paul J. ;
Llovet, Josep M. ;
Leberre, Marie-Aude ;
Jensen, Markus ;
Meinhardt, Gerold ;
Kang, Yoon-Koo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :559-566
[86]  
Zuo HQ, 2007, HEPATOB PANCREAT DIS, V6, P161